Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 25 peer-reviewed journal articles Updated
Immunology

Modern Treatment: Prophylaxis and On-Demand Therapy

At a Glance

Modern treatment for HAE Type 1 focuses on total disease control using two methods: long-term prophylaxis to prevent attacks and on-demand rescue therapy to stop active swelling. Patients are encouraged to use targeted therapies and self-administer medications at home for the best outcomes.

The world of Hereditary Angioedema (HAE) Type 1 has changed dramatically in the last decade. We have moved from an era of simply “managing emergencies” to a modern standard of care where the goal is total disease control [1][2]. Current international guidelines (WAO/EAACI) emphasize that patients should be able to live a life that is “normalized,” meaning you shouldn’t have to plan your life around the fear of an attack [3].

The Two-Pronged Strategy

To achieve this control, modern treatment uses two distinct approaches:

  1. On-Demand (Acute) Therapy: This is your “fire extinguisher.” It is a medication you use to stop an attack that has already started [4]. Guidelines recommend treating at the very first sign of an attack, as early intervention significantly shortens the duration and prevents dangerous progression [5].
  2. Long-Term Prophylaxis (LTP): This is your “fire prevention” system. These are medications taken regularly (even when you feel fine) to prevent attacks from ever beginning [6][7].

Modern Preventative Options (LTP)

Unlike older treatments, modern prophylaxis is designed to target the specific biology of HAE with fewer systemic side effects. Note: Securing these specialized medications often requires coordinating with specialty pharmacies and insurance prior-authorizations; your doctor’s office or patient advocacy groups can help navigate this process.

Medication How it’s taken How it works Potential Side Effects
Lanadelumab Subcutaneous (under-the-skin) injection every 2-4 weeks Blocks the kallikrein protein that creates bradykinin [8] Injection-site pain, redness, or bruising [9]
Berotralstat One oral pill taken daily A daily pill that inhibits kallikrein [10] Gastrointestinal upset (nausea or diarrhea) [9]
Subcutaneous C1-INH Injection twice weekly Replaces the missing C1-inhibitor protein [11] Injection-site reactions [12]

On-Demand (Rescue) Medications

Every patient, even those who rarely have attacks, must always have access to at least two doses of an approved on-demand treatment [5][13].

  • Icatibant: A pre-filled syringe you inject under the skin of your abdomen. It blocks the bradykinin receptor to stop the swelling signal [14][15]. Important: It is completely normal to experience intense temporary burning, stinging, redness, and swelling at the injection site when using Icatibant. Do not panic—this is an expected reaction to the drug, not a sign of an allergic reaction.
  • pdC1-INH (IV): An intravenous replacement of the missing protein that “shuts off” the swelling process at its source [16][17].
  • Other Options: Depending on availability, your doctor might also discuss options like Ecallantide (Kalbitor) or recombinant C1-INH (Ruconest) as alternative rescue therapies [18][19].

Moving Away from the Past

You may hear about older treatments like attenuated androgens (e.g., Danazol or Stanozolol) or tranexamic acid. While these were once the only options, modern guidelines now discourage their use as first-line therapy [20][21].

  • Androgens carry risks of long-term liver damage, weight gain, and significant drug-drug interactions [20][22].
  • Tranexamic Acid is generally much less effective than modern targeted therapies [21][23].

The Importance of Self-Administration

The current standard of care is that all patients should be trained to self-administer their own medications [19][24]. Being able to treat yourself at home—rather than waiting in an ER—not only speeds up your recovery but also provides a sense of freedom and safety that is essential for living a full life with HAE [25].

Common questions in this guide

What is the difference between prophylaxis and on-demand HAE treatment?
On-demand therapy is used to stop an active HAE attack as soon as it begins. Prophylaxis involves taking medication regularly, even when you feel fine, to prevent attacks from happening in the first place.
When should I use my HAE rescue medication?
Guidelines recommend using your on-demand rescue medication at the very first sign of an attack. Early intervention stops the swelling faster and prevents the attack from becoming severe.
Is it normal for my Icatibant injection site to burn and swell?
Yes, it is completely normal to experience intense temporary burning, stinging, redness, and swelling where you inject Icatibant. This is an expected reaction to the medication, not an allergic response.
Are older treatments like Danazol still recommended for HAE?
Modern guidelines generally discourage the use of older treatments like attenuated androgens (Danazol) due to risks of liver damage and side effects. Targeted modern therapies with fewer systemic risks are now the standard of care.
Should I learn how to self-administer my HAE medication?
Yes, the current standard of care recommends that all patients learn to self-administer their HAE treatments. Treating yourself at home speeds up recovery and provides more freedom compared to waiting in an emergency room.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Which modern prophylactic option (daily pill or bi-weekly injection) best fits my lifestyle and clinical profile?
  2. 2.Can you provide a 'Step-by-Step' training session for me or my caregiver on how to use my on-demand rescue medication?
  3. 3.If I am currently on Danazol or other androgens, what is our plan for safely tapering off these and switching to a more targeted therapy?
  4. 4.How many doses of rescue medication should I keep at home, and how many should I carry with me when I travel?
  5. 5.Are there newer treatments currently in clinical trials or recently approved that might be relevant for my specific case?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (25)
  1. 1

    Consensus on treatment goals in hereditary angioedema: A global Delphi initiative.

    Maurer M, Aygören-Pürsün E, Banerji A, et al.

    The Journal of allergy and clinical immunology 2021; (148(6)):1526-1532 doi:10.1016/j.jaci.2021.05.016.

    PMID: 34048855
  2. 2

    Diagnosis and screening of patients with hereditary angioedema in primary care.

    Henao MP, Kraschnewski JL, Kelbel T, Craig TJ

    Therapeutics and clinical risk management 2016; (12()):701-11 doi:10.2147/TCRM.S86293.

    PMID: 27194914
  3. 3

    A Treat-to-Target approach in hereditary angioedema: expert consensus from a European committee.

    Cancian M, Caballero T, Boccon-Gibod I, et al.

    Frontiers in immunology 2026; (17()):1773279 doi:10.3389/fimmu.2026.1773279.

    PMID: 41766887
  4. 4

    Hereditary angioedema: how to approach it at the emergency department?

    Serpa FS, Mansour E, Aun MV, et al.

    Einstein (Sao Paulo, Brazil) 2021; (19()):eRW5498 doi:10.31744/einstein_journal/2021RW5498.

    PMID: 33852678
  5. 5

    Breakthrough attacks in patients with hereditary angioedema receiving long-term prophylaxis are responsive to icatibant: findings from the Icatibant Outcome Survey.

    Aberer W, Maurer M, Bouillet L, et al.

    Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology 2017; (13()):31 doi:10.1186/s13223-017-0203-z.

    PMID: 28690642
  6. 6

    Treatment Patterns and Characteristics of Patients with Hereditary Angioedema Treated with Lanadelumab: A US Retrospective Chart Review.

    Watt M, Chang R, Yu LH, et al.

    Drugs - real world outcomes 2025; (12(3)):351-365 doi:10.1007/s40801-025-00505-x.

    PMID: 40665203
  7. 7

    Garadacimab for hereditary angioedema attack prevention: long-term efficacy, quality of life, and safety data from a phase 2, randomised, open-label extension study.

    Craig TJ, Levy DS, Reshef A, et al.

    The Lancet. Haematology 2024; (11(6)):e436-e447 doi:10.1016/S2352-3026(24)00081-4.

    PMID: 38710185
  8. 8

    A review of kallikrein inhibitor lanadelumab in hereditary angioedema.

    Hwang G, Johri A, Ng S, Craig T

    Immunotherapy 2019; (11(11)):937-944 doi:10.2217/imt-2018-0197.

    PMID: 31234673
  9. 9

    Hereditary Angioedema Prophylaxis Therapy: Berotralstat and Lanadelumab Safety Profile.

    Donadoni M, La Cava L, Bizzi E, et al.

    Medicina (Kaunas, Lithuania) 2025; (61(11)) doi:10.3390/medicina61111897.

    PMID: 41303734
  10. 10

    Berotralstat (BCX7353): Structure-Guided Design of a Potent, Selective, and Oral Plasma Kallikrein Inhibitor to Prevent Attacks of Hereditary Angioedema (HAE).

    Kotian PL, Wu M, Vadlakonda S, et al.

    Journal of medicinal chemistry 2021; (64(17)):12453-12468 doi:10.1021/acs.jmedchem.1c00511.

    PMID: 34436898
  11. 11

    Hereditary and acquired angioedema.

    Patel G, Pongracic JA

    Allergy and asthma proceedings 2019; (40(6)):441-445 doi:10.2500/aap.2019.40.4267.

    PMID: 31690390
  12. 12

    Long-term Prophylaxis with Androgens in the management of Hereditary Angioedema (HAE) in emerging countries.

    Guo Y, Zhang H, Lai H, et al.

    Orphanet journal of rare diseases 2022; (17(1)):399 doi:10.1186/s13023-022-02536-x.

    PMID: 36324138
  13. 13

    Analysis of prodromal symptoms and need for short-term prophylaxis in angioedema patients under long-term prophylaxis.

    Lochbaum R, Hoffmann TK, Greve J, Hahn J

    Orphanet journal of rare diseases 2025; (20(1)):47 doi:10.1186/s13023-025-03562-1.

    PMID: 39893484
  14. 14

    Safety and efficacy of C1 esterase inhibitor for acute attacks in children with hereditary angioedema.

    Lumry W, Soteres D, Gower R, et al.

    Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology 2015; (26(7)):674-80 doi:10.1111/pai.12444.

    PMID: 26171584
  15. 15

    Management of patients with hereditary angioedema in Germany: comparison with other countries in the Icatibant Outcome Survey.

    Maurer M, Bork K, Martinez-Saguer I, et al.

    Journal of the European Academy of Dermatology and Venereology : JEADV 2019; (33(1)):163-169 doi:10.1111/jdv.15232.

    PMID: 30176179
  16. 16

    A Two-Decade-Delayed Diagnosis of Hereditary Angioedema: A Case Report.

    Shrestha S, Yadav AK, Khadka D, et al.

    Cureus 2025; (17(5)):e85019 doi:10.7759/cureus.85019.

    PMID: 40585652
  17. 17

    Hereditary Angioedema and Gastrointestinal Complications: An Extensive Review of the Literature.

    Patel N, Suarez LD, Kapur S, Bielory L

    Case reports in immunology 2015; (2015()):925861 doi:10.1155/2015/925861.

    PMID: 26339513
  18. 18

    A new oral kallikrein inhibitor for long-term prophylaxis of hereditary angioedema.

    Doña I, Torres MJ

    Allergy 2021; (76(6)):1619-1620 doi:10.1111/all.14798.

    PMID: 33641193
  19. 19

    Hereditary angioedema: an update on causes, manifestations and treatment.

    Longhurst HJ, Bork K

    British journal of hospital medicine (London, England : 2005) 2019; (80(7)):391-398 doi:10.12968/hmed.2019.80.7.391.

    PMID: 31283393
  20. 20

    Assessment of potential drug-drug interactions in patients with hereditary angioedema from the ITACA cohort: simulations from a real-life dataset considering danazol versus berotralstat.

    Zanichelli A, Cattaneo D, Gidaro A, et al.

    Frontiers in pharmacology 2025; (16()):1550133 doi:10.3389/fphar.2025.1550133.

    PMID: 40351426
  21. 21

    Real-World Evidence on the Management of Hereditary Angioedema With Normal C1 Inhibitor.

    Lobão NTM, Bardou MLD, Vila SYC, et al.

    The journal of allergy and clinical immunology. In practice 2026; (14(1)):233-242.e2 doi:10.1016/j.jaip.2025.10.001.

    PMID: 41077399
  22. 22

    Delphi Consensus on Attenuated Androgen Use for Long-Term Prophylaxis in Hereditary Angioedema: AURA Project.

    Dias de Castro E, Cardoso LM, Jácome de Castro J, Ferreira MB

    Clinical and translational allergy 2025; (15(11)):e70116 doi:10.1002/clt2.70116.

    PMID: 41219138
  23. 23

    Transition to lanadelumab-flyo from three medications for a hereditary angioedema patient with a variant in the SYTL2 gene: A case report.

    Burns S, Lewis E

    Clinical case reports 2021; (9(4)):2438-2441 doi:10.1002/ccr3.4060.

    PMID: 33936709
  24. 24

    Current medical management of hereditary angioedema: Follow-up survey of US physicians.

    Riedl MA, Banerji A, Gower R

    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 2021; (126(3)):264-272 doi:10.1016/j.anai.2020.10.009.

    PMID: 33122123
  25. 25

    Health-Related Quality of Life with Subcutaneous C1-Inhibitor for Prevention of Attacks of Hereditary Angioedema.

    Lumry WR, Craig T, Zuraw B, et al.

    The journal of allergy and clinical immunology. In practice 2018; (6(5)):1733-1741.e3 doi:10.1016/j.jaip.2017.12.039.

    PMID: 29391286

This page provides educational information about modern HAE Type 1 treatments. Always consult your immunologist or allergy specialist before changing medications or your treatment plan.

Get notified when new evidence is published on Hereditary angioedema type 1.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.